Black Diamond Therapeutics Enters Material Definitive Agreement
Ticker: BDTX · Form: 8-K · Filed: Mar 19, 2025 · CIK: 1701541
| Field | Detail |
|---|---|
| Company | Black Diamond Therapeutics, Inc. (BDTX) |
| Form Type | 8-K |
| Filed Date | Mar 19, 2025 |
| Risk Level | medium |
| Sentiment | neutral |
Sentiment: neutral
Topics: material-agreement, corporate-action
Related Tickers: BDTX
TL;DR
BDTX signed a big deal, details to come.
AI Summary
Black Diamond Therapeutics, Inc. announced on March 18, 2025, that it entered into a material definitive agreement. The company, formerly known as Aset Therapeutics, Inc. until March 21, 2017, is based in Cambridge, MA.
Why It Matters
This filing indicates a significant new contract or partnership for Black Diamond Therapeutics, which could impact its future operations and financial performance.
Risk Assessment
Risk Level: medium — Entering a material definitive agreement can carry significant risks related to the terms, counterparty, and execution of the agreement.
Key Players & Entities
- Black Diamond Therapeutics, Inc. (company) — Registrant
- Aset Therapeutics, Inc. (company) — Former company name
- March 18, 2025 (date) — Date of earliest event reported
- March 21, 2017 (date) — Date of former company name change
- Cambridge, MA (location) — Company headquarters
FAQ
What is the nature of the material definitive agreement entered into by Black Diamond Therapeutics?
The filing states that Black Diamond Therapeutics, Inc. entered into a material definitive agreement on March 18, 2025, but the specific details of the agreement are not provided in this excerpt.
When was Black Diamond Therapeutics, Inc. formerly known as Aset Therapeutics, Inc.?
Black Diamond Therapeutics, Inc. was formerly known as Aset Therapeutics, Inc. until March 21, 2017.
What is the principal executive office address for Black Diamond Therapeutics, Inc.?
The principal executive offices of Black Diamond Therapeutics, Inc. are located at One Main Street, 14th Floor, Cambridge, MA 02142.
What is the Commission File Number for Black Diamond Therapeutics, Inc.?
The Commission File Number for Black Diamond Therapeutics, Inc. is 001-39200.
What is the SIC code for Black Diamond Therapeutics, Inc.?
The Standard Industrial Classification (SIC) code for Black Diamond Therapeutics, Inc. is 2836, which corresponds to BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES).
Filing Details
This Form 8-K (Form 8-K) was filed with the SEC on March 19, 2025 regarding Black Diamond Therapeutics, Inc. (BDTX).